Achaogen Signs $26.6 Million Contract With National Institute of Allergy And Infectious Diseases (NIAID)
Published: Mar 03, 2009
Achaogen’s neoglycosides, next-generation aminoglycosides, have shown broad-spectrum efficacy in vitro and in vivo against a wide range of multi-drug resistant Gram-negative organisms (including Pseudomonas, Acinetobacter and Enterobacteriaceae) as well as multi-drug resistant Gram-positive bacteria (including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Staphylococcus strains). The NIAID funding will support Achaogen work to extend the spectrum and efficacy of its current leads, and to advance one neoglycoside through Phase 1 clinical trials.
“We are delighted that Achaogen has successfully competed for funding to advance our pipeline of novel therapies to multi-drug resistant antibacterial infections, including our expanded-spectrum neoglycosides portfolio,” said J. Kevin Judice, Ph.D., chief executive officer and chief scientific officer of Achaogen. “Achaogen shares NIAID’s commitment to addressing the global concerns of biothreat bacteria and antibiotic resistance. We are excited to be at the forefront of the development of potential solutions to these concerns.”
The project will be 100% federally funded in the amount of $26,660,078.
Achaogen is a clinical stage biopharmaceutical company focused on the discovery and development of innovative, broad-spectrum antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is poised to meet the evolving needs of this market by applying its anticipatory science to develop drugs today that will combat tomorrow’s resistant pathogens. This scientific strategy represents a novel approach to addressing the global bacterial resistance crisis. Achaogen is creating new medicines that anticipate the next wave of anti-bacterial infections, including agents for the underserved Gram-negative infectious disease market and methicillin-resistant Staphylococcus aureus (MRSA). Achaogen’s most advanced compound, ACHN-490, one of the company’s next generation aminoglycosides known as neoglycosides, entered the clinic in January 2009, and the company has several other innovative small molecule antibacterial programs nearing clinical development. South San Francisco-based Achaogen is backed by top-tier venture investors and has received substantial non-dilutive funding from NIH, the U.S. Department of Defense, the Wellcome Trust and other sources. Venture capital investors include 5 AM Ventures, ARCH Venture Partners and Domain Associates, Venrock Associates and Versant Ventures. For more information, please visit the company’s website at www.achaogen.com.
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports research - at the National Institutes of Health (NIH), throughout the United States, and worldwide - to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.
The NIH - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
Pure Communications Ashlea Kosikowski, 910-547-7093